文献速递创伤与烧伤复苏、休克与脓毒症

四因子凝血酶原复合物在创伤性凝血病中的作用:倾向性匹配分析

The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论在严重创伤凝血病患者中,4-PCC联合FFP较单用FFP更快纠正INR、减少输血需求并降低死亡率,但为IV级证据的回顾性研究。

本研究为单中心回顾性倾向性匹配分析,纳入2015至2016年收治的516例成人创伤患者,排除伤前口服抗凝药者,最终匹配120例(4-PCC+FFP组40例,FFP组80例)。凝血病定义为入院INR>1.5,INR纠正定义为≤1.5。与单用FFP相比,4-PCC+FFP组INR纠正时间更短(373分钟 vs 955分钟,p=0.001),输注红细胞更少(7单位 vs 9单位,p=0.04),FFP更少(5单位 vs 7单位,p=0.03),死亡率更低(25% vs 33%,p=0.04),血栓栓塞并发症无差异(2.5% vs 1.2%,p=0.5)。作者认为4-PCC联合FFP优于单用FFP用于逆转创伤性凝血病。

要点

  • 在入院INR>1.5的成人创伤患者中,4-PCC+FFP组INR纠正时间为373分钟,单用FFP组为955分钟(p=0.001)。
  • 4-PCC+FFP组输注红细胞7单位、FFP 5单位,分别少于单用FFP组的9单位和7单位(p=0.04和p=0.03)。
  • 4-PCC+FFP组死亡率为25%,单用FFP组为33%(p=0.04)。
  • 两组血栓栓塞并发症发生率分别为2.5%和1.2%,差异无统计学意义(p=0.5)。
  • 该研究为单中心回顾性倾向性匹配分析,证据等级为IV级。

适用人群与场景

  • 年龄大于18岁、在Level I创伤中心接受4-PCC+FFP或单用FFP治疗的创伤患者。
  • 排除伤前口服抗凝药的患者。
  • 凝血病定义为入院INR>1.5。

诊断标准与关键阈值

  • 创伤性凝血病(COT)定义为入院INR>1.5。
  • INR纠正定义为INR≤1.5。

研究设计与关键结果

  • 研究类型为单中心回顾性倾向性匹配分析,2015至2016年共分析516例创伤患者,按1:2比例匹配后纳入120例(4-PCC+FFP组40例,FFP组80例)。
  • 匹配队列平均年龄58±20岁,男性占60%,中位损伤严重度评分为29(14-38),钝性损伤占87%。
  • 4-PCC+FFP组INR纠正时间为373分钟,单用FFP组为955分钟(p=0.001)。
  • 4-PCC+FFP组输注红细胞7单位,单用FFP组为9单位(p=0.04);4-PCC+FFP组输注FFP 5单位,单用FFP组为7单位(p=0.03)。
  • 4-PCC+FFP组死亡率为25%,单用FFP组为33%(p=0.04)。
  • 血栓栓塞并发症发生率4-PCC+FFP组为2.5%,单用FFP组为1.2%,差异无统计学意义(p=0.5)。

证据类型、等级与局限

  • 证据类型为治疗性研究,证据等级为IV级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,4-PCC作为联合FFP的组分治疗,在逆转创伤性凝血病方面优于单用FFP。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Coagulopathy is a common complication after severe trauma. The efficacy of 4-factor prothrombin complex concentrate (4-PCC) as an adjunct to fresh frozen plasma (FFP) in reversal of coagulopathy of trauma (COT) has not been studied. The aim of our study is to compare 4-PCC + FFP versus FFP alone for the treatment of COT.

METHODS: We reviewed all trauma patients older than 18 years who received PCC + FFP or FFP alone at our Level I trauma center from 2015 to 2016. We excluded patients on preinjury oral anticoagulants. Patients were divided into two groups (4-PCC + FFP: FFP alone) and were matched in a 1:2 ratio using propensity score matching for demographics, vital and injury parameters, and initial international normalized ratio (INR). COT was defined as admission INR > 1.5. Corrected INR was defined as an INR of 1.5 or less. Outcome measures were time to correction of INR, packed red blood cells units transfused, thromboembolic complications, and mortality.

RESULTS: We analyzed 516 trauma patients, of which 120 patients (4-PCC + FFP: 40, FFP: 80) were matched. Mean age was 58 ± 20 years; 60% were male, median Injury Severity Score was 29 (14-38). Mechanism of injury was blunt in 87% patients. 4-PCC + FFP was associated with an accelerated correction of INR (373 minutes vs. 955 minutes; p = 0.001), a decrease in packed red blood cells units (7 units vs. 9 units; p = 0.04), and FFP units (5 units vs. 7 units; p = 0.03) transfused compared to FFP alone. 4-PCC + FFP was associated with a lower mortality (25% vs. 33% p = 0.04) compared with FFP alone; however, there was no difference in the thromboembolic complications (2.5% vs. 1.2%, p = 0.5) between the two groups. Administration of PCC + FFP led to an earlier correction of the INR compared with FFP alone.

CONCLUSION: Results of our study demonstrated that the use of 4-PCC in conjunction with FFP is associated with the rapid reversal of INR and reduction in transfusion requirements as compared with FFP alone. Four-factor PCC as a component therapy along with FFP is superior to FFP alone for the reversal of COT.

LEVEL OF EVIDENCE: Therapeutic studies, level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Jehan F, Aziz H, OʼKeeffe T, et al. The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis. J Trauma Acute Care Surg. 2018. PMID: 29664892. doi:10.1097/TA.0000000000001938

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。